Product pipeline
Our company is committed to developing transdermal patch and oral film drug products with clinical advantages such as lower toxicity, higher efficacy, and better patient compliance than oral tablets. In a few years, we will provide several blockbuster new drugs to patients in China and the world to meet the unmet medical needs. We will become a world-leading pharmaceutical company in transdermal patch and oral film drug products. Our product portfolio under research includes a dozen US 505(b)(2) (China Class II) new drugs, several of which are expected to become blockbuster new drugs.